A Phase 3 interventional study of Rosuvastatin and Placebo in Familial Hypercholesterolemia, sponsored by AstraZeneca. Completed at 20 sites in 5 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2011-08-31.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands — 5 open to participants now, 7 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Netherlands.
Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, this one is the 14th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2006, is one of 14 in phase 3, and was the 7th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →5 of the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Australia and 17 more countries
Ages 6–17
Novartis Pharmaceuticals · Sites in Netherlands, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Netherlands, United States, Argentina and 20 more countries
Ages 6–11
Verve Therapeutics, Inc. · Sites in Netherlands, United States, Australia and 3 more countries
Ages 18–70
Novartis Pharmaceuticals · Sites in Netherlands, United States, Argentina and 23 more countries
Ages 2–100
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 17 · Phase 4 1
First in 2000; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 173 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 153 across the 33 interventional studies, 29 across the 2 observational. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 35 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 4 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the efficacy of once-daily rosuvastatin in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day 0) to the end of the 12-week double-blind treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
rosuvastatin 5 mg
Drug: Rosuvastatin
rosuvastatin 10 mg
Drug: Rosuvastatin
rosuvastatin 20 mg
Drug: Rosuvastatin
Placebo
Drug: Placebo
rosuvastatin open label
Drug: Rosuvastatin
oral
Also known as: Nexium
oral
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase
Percent change in low-density lipoprotein cholesterol (LDL-C) = (final value - Baseline value)/Baseline value \* 100
Time frame: 12 weeks
Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)
Percent change from baseline in LDL-C after six week of treatment
Time frame: 6 weeks
Percent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment
Percent of patients achieving LDL-C \< 110 mg/dL out of the total patients in each treatment group
Time frame: 12 weeks
Percent Change in HDL-C
Percent change in high-density lipoprotein cholesterol (HDL-C) after 12 weeks of treatment
Time frame: After 12 weeks of treatment
Percent Change in Non-HDL-C at 12 Weeks
Percent change in non-HDL-C at 12 weeks
Time frame: After 12 weeks of treatment
Percent Change in Triglycerides (TG)
Percent change in tryglycerides (TG) after 12 weeks of treatment
Time frame: After 12 weeks of treatment
Percent Change in Total Cholesterol (TC)
Percent change from baseline in total cholesteral after 12 weeks of treatment
Time frame: After 12 weeks of treatment
Percent Change in Apolipoprotein A-1 (ApoA-1)
Percent change in ApoA-1 after 12 weeks of treatment
Time frame: After 12 weeks of treatment
Percent Change in Apolipoprotein B (ApoB)
Percent change in ApoB after 12 weeks of treatment
Time frame: After 12 weeks of treatment
Percent Change in ApoB/ApoA-1
Percent change in the ratio of ApoB/ApoA-1 after 12 weeks of treatment
Time frame: After 12 weeks of treatment
Percent Change in LDL-C/HDL-C
Percent change in the ratio of LDL-C/HDL-C after 12 weeks of treatment
Time frame: After 12 week of treatment
Percent Change in TC/HDL-C
Percent change in the ratio of TC/HDL-C after 12 weeks of treatment
Time frame: After 12 weeks of treatment
Percent Change in Non-HDL-C/HDL-C
Percent change in the ratio of non-HDL-C/HDL-C after 12 weeks of treatment
Time frame: After 12 weeks of treatment
One-hundred male and female (Tanner stages II to V, at least 1 year post-menarche) children and adolescents (aged 10 to 17 years with Heterozygous familial hypercholesterolemia were randomized into the study, from 20 sites located in The United States (3 sites), The Netherlands (7 sites), Norway (1 site), Spain (3 sites), and Canada (6 sites).
| Milestone | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo | Rosuva ol |
|---|---|---|---|---|---|
| Started | 42 | 44 | 45 | 46 | 0 |
| Completed | 41 | 44 | 44 | 45 | 0 |
| Not completed | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 | 0 |
| Milestone | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo | Rosuva ol |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 173 |
| Completed | 0 | 0 | 0 | 0 | 164 |
| Not completed | 0 | 0 | 0 | 0 | 9 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Investigational site closed | 0 | 0 | 0 | 0 | 1 |
Percent change in low-density lipoprotein cholesterol (LDL-C) = (final value - Baseline value)/Baseline value \* 100
| percentage | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase | -38.5 ± 11.38 | -44.4 ± 12.15 | -50.2 ± 13.3 | -0.5 ± 13.18 |
Percent change from baseline in LDL-C after six week of treatment
| percentage | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12) | -40.3 ± 12.22 | -45.2 ± 11.15 | -50.0 ± 11.42 | -0.6 ± 13.63 |
Percent of patients achieving LDL-C \< 110 mg/dL out of the total patients in each treatment group
| Percent of Participants | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment | 11.9 | 40.9 | 40.9 | 0.0 |
Percent change in high-density lipoprotein cholesterol (HDL-C) after 12 weeks of treatment
| percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in HDL-C | 4.5 ± 15.53 | 10.1 ± 14.19 | 8.9 ± 14.11 | 7.6 ± 17.89 |
Percent change in non-HDL-C at 12 weeks
| percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in Non-HDL-C at 12 Weeks | -36.3 ± 9.98 | -42.8 ± 11.50 | -47.7 ± 13.50 | -0.8 ± 11.89 |
Percent change in tryglycerides (TG) after 12 weeks of treatment
| percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in Triglycerides (TG) | 2.6 ± 49.07 | -14.2 ± 29.66 | -7.9 ± 55.88 | 3.4 ± 48.27 |
Percent change from baseline in total cholesteral after 12 weeks of treatment
| percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in Total Cholesterol (TC) | -30.0 ± 9.63 | -34.1 ± 9.5 | -38.9 ± 12.08 | 0.2 ± 10.53 |
Percent change in ApoA-1 after 12 weeks of treatment
| mean percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in Apolipoprotein A-1 (ApoA-1) | 2.3 ± 9.69 | 4.3 ± 9.85 | 3.9 ± 10.68 | 3.6 ± 15.59 |
Percent change in ApoB after 12 weeks of treatment
| mean percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in Apolipoprotein B (ApoB) | -32.1 ± 9.13 | -37.8 ± 11.75 | -40.7 ± 13.91 | -1.5 ± 14.67 |
Percent change in the ratio of ApoB/ApoA-1 after 12 weeks of treatment
| mean percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in ApoB/ApoA-1 | -33.1 ± 9.99 | -40.0 ± 12.06 | -42.8 ± 12.23 | -3.4 ± 16.70 |
Percent change in the ratio of LDL-C/HDL-C after 12 weeks of treatment
| mean percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in LDL-C/HDL-C | -40.4 ± 11.36 | -48.6 ± 13.26 | -53.6 ± 12.85 | -5.5 ± 17.98 |
Percent change in the ratio of TC/HDL-C after 12 weeks of treatment
| mean percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in TC/HDL-C | -32.1 ± 10.72 | -39.3 ± 11.55 | -43.2 ± 11.76 | -5.2 ± 15.03 |
Percent change in the ratio of non-HDL-C/HDL-C after 12 weeks of treatment
| mean percent change | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo |
|---|---|---|---|---|
| Percent Change in Non-HDL-C/HDL-C | -37.9 ± 12.12 | -47.1 ± 13.12 | -51.2 ± 13.18 | -5.8 ± 17.63 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuva 5 | — | — | — |
| Rosuva 10 | — | — | — |
| Rosuva 20 | — | — | — |
| Placebo | — | — | — |
| Rosuva ol | — | — | — |
| Event | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo | Rosuva ol |
|---|---|---|---|---|---|
| Vision BlurredEye disorders | 0/42 | 0/44 | 0/44 | 1/46 | 0/173 |
| AppendicitisInfections and infestations | 0/42 | 0/44 | 0/44 | 0/46 | 1/173 |
| Rash VesicularSkin and subcutaneous tissue disorders | 0/42 | 0/44 | 0/44 | 0/46 | 1/173 |
| Event | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo | Rosuva ol |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/42 | 7/44 | 7/44 | 5/46 | 36/173 |
| HeadacheNervous system disorders | 6/42 | 7/44 | 9/44 | 9/46 | 29/173 |
| InfluenzaInfections and infestations | 2/42 | 2/44 | 0/44 | 4/46 | 14/173 |
| TonsillitisGastrointestinal disorders | 0/42 | 0/44 | 3/44 | 1/46 | 2/173 |
| NauseaGastrointestinal disorders | 2/42 | 0/44 | 2/44 | 2/46 | 10/173 |
| FatigueGeneral disorders | 1/42 | 1/44 | 1/44 | 0/46 | 9/173 |
| Age Continuous(years) | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 14.1 (10 to 17) | 14.5 (11 to 17) | 14.2 (11 to 17) | 14.3 (10 to 17) | 14.3 (10 to 17) |
| Sex: Female, Male(Participants) | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 26 | 25 | 22 | 24 | 97 |
| Male | 16 | 19 | 23 | 22 | 80 |
| Baseline low-density lipoprotein cholesterol (LDL-C)(mg/dL) | Rosuva 5 | Rosuva 10 | Rosuva 20 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 237.70 ± 55.06 | 229.10 ± 44.70 | 237.40 ± 47.80 | 229.00 ± 43.13 | 233.3 ± 10.0 |
The record gives a start of Jul 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin
Hyperlipoproteinemia Type II →